Injectable chitosan hydrogel effectively controls lesion growth in a venous malformation murine model.

Autor: Nguyen HL; Human Molecular Genetics, de Duve Institute, University of Louvain, B-1200 Brussels, Belgium., Holderbaum Do Amaral R; Centre Hospitalier de l'Université de Montréal Research Center (CRCHUM), Montreal, QC, H2 × 0A9, Canada; Department of Radiology, Radiation Oncology and Nuclear Medicine, Université de Montreal, Montreal, QC, H3T 1J4, Canada., Lerouge S; Centre Hospitalier de l'Université de Montréal Research Center (CRCHUM), Montreal, QC, H2 × 0A9, Canada; Department of Radiology, Radiation Oncology and Nuclear Medicine, Université de Montreal, Montreal, QC, H3T 1J4, Canada; Department of Mechanical Engineering, Ecole de Technologie Supérieure (ÉTS), Montreal, QC, H3C 1K3, Canada., De Roo AK; Department of Pathology, Saint Luc University Hospital, B-1200 Brussels, Belgium; Institute of Experimental and Clinical Research, University of Louvain, B-1348 Brussels, Belgium; Center for Vascular Anomalies, Member of VASCERN (European Reference Network on Rare Multisystemic Vascular Diseases) VASCA European Reference Centre Cliniques Universitaires Saint-Luc, B-1200 Brussels, Belgium., Zehtabi F; Centre Hospitalier de l'Université de Montréal Research Center (CRCHUM), Montreal, QC, H2 × 0A9, Canada; Department of Mechanical Engineering, Ecole de Technologie Supérieure (ÉTS), Montreal, QC, H3C 1K3, Canada., Vikkula M; Human Molecular Genetics, de Duve Institute, University of Louvain, B-1200 Brussels, Belgium; WELBIO Department, WEL Research Institute, B-1300 Wavre, Belgium., Soulez G; Centre Hospitalier de l'Université de Montréal Research Center (CRCHUM), Montreal, QC, H2 × 0A9, Canada; Department of Radiology, Radiation Oncology and Nuclear Medicine, Université de Montreal, Montreal, QC, H3T 1J4, Canada. Electronic address: gilles.soulez.med@ssss.gouv.qc.ca.
Jazyk: angličtina
Zdroj: Diagnostic and interventional imaging [Diagn Interv Imaging] 2024 Nov; Vol. 105 (11), pp. 430-438. Date of Electronic Publication: 2024 Aug 02.
DOI: 10.1016/j.diii.2024.07.004
Abstrakt: Purpose: The purpose of this study was to evaluate the safety and efficacy of intralesional injection of chitosan hydrogel (CH) combined with sodium tetradecyl sulfate (STS) to sclerose and embolize venous malformations (VMs) by comparison with 3% STS foam and placebo in a mouse model.
Materials and Methods: Subcutaneous VMs were created by injecting HUVEC_TIE2-L914F cells, mixed with matrigel, into the back of athymic mice (Day [D] 0). After VM-like lesions were established at D10, 70 lesions were randomly assigned to one of six treatment groups (untreated, saline, 3% STS-foam, CH, 1% STS-CH, 3% STS-CH). For 3% STS-foam, the standard Tessari technique was performed. VMs were regularly evaluated every 2-3 days to measure lesion size until the time of collection at D30 (primary endpoint). At D30, VM lesions including the matrigel plugs were culled and evaluated by histological analysis to assess vessel size, chitosan distribution and endothelial expression. One-way analysis of variance (ANOVA) test was performed to compare quantitative variables with normal distribution, otherwise Kruskal-Wallis test followed by pairwise comparisons by a Wilcoxon rank sum test was performed.
Results: All VMs were successfully punctured and injected. Six VMs injected with 3% STS-CH showed early skin ulceration with an extrusion of the matrigel plug and were excluded from final analysis. In the remaining 64 VMs, skin ulceration occurred on 26 plugs, resulting in the loss of three 3% STS-foam and one 1% STS-CH plugs. Both chitosan formulations effectively controlled growth of VMs by the end of follow-up compared to untreated or 3% STS-foam groups (P < 0.05). Vessel sizes were smaller with both CH formulations compared to untreated and saline groups (P < 0.05). Additionally, there were smaller vascular channels within the 1% STS-CH group compared to the 3% STS-foam group (P < 0.05).
Conclusion: Chitosan's ability to control the growth of VMs suggests a promising therapeutic effect that outperforms the gold standard (STS-foam) on several variables.
Competing Interests: Declaration of competing interest Gilles Soulez and Sophie Lerouge have patented the STS-CH hydrogel (A sclerosing and embolizing gel, US publication number: 8840867 B2, 23 Sept. 2014, Patent Appl. CA 2704,971, May 2010. Licensed to Cook Medical). They also act as consultants for Cook Medical.
(Copyright © 2024 Société française de radiologie. Published by Elsevier Masson SAS. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: